» Articles » PMID: 28009651

A Review of Cognitive Screening Tools in Cancer

Overview
Date 2016 Dec 24
PMID 28009651
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Cancer-related cognitive impairment (CRCI) is highly prevalent, and assessment of cognition is crucial in providing optimal cancer care. Neuropsychological assessment (NPA) can be lengthy and expensive. Cognitive screening tools are plenty but validity has not been thoroughly studied for use in cancer patients.

Recent Findings: Our search of the recent literature revealed that the Montreal Cognitive Assessment, Mini-Mental State Examination, and Clock Draw Test were the most frequently studied objective screening tools. The Functional Assessment of Cancer Therapy-Cognitive Function and the Cognitive Symptom Checklist-Work 21 were the most commonly studied subjective measures of perceived cognitive impairment. Evidence supports using the Montreal Cognitive Assessment or the Clock Draw Test over the Mini-Mental State Examination to screen for cognitive impairment within specific patient populations. In addition, adding a subjective measure of cognitive impairment (e.g., Functional Assessment of Cancer Therapy-Cognitive Function) may increase diagnostic sensitivity.

Summary: These suggest that cognitive screening tools may have a role in screening for CRCI, particularly when full NPA is not feasible. Researchers must continue to conduct high-quality studies to build an evidence to guide best practices in screening for CRCI.

Citing Articles

Role of intergenerational connections in cognitive aging: Evidence from a Chinese longitudinal study.

Hu S, Ge J, Fang M, Yang J Front Public Health. 2024; 12:1396620.

PMID: 39234093 PMC: 11371578. DOI: 10.3389/fpubh.2024.1396620.


Correlation between cancer-related cognitive impairment and resting cerebral glucose metabolism in patients with ovarian cancer.

Wang L, Hu S, Yao Z, Xue M, Lu Z, Xiao-Ju Z Heliyon. 2024; 10(14):e34106.

PMID: 39113970 PMC: 11305194. DOI: 10.1016/j.heliyon.2024.e34106.


Measurement of Cognitive Function in Exercise Oncology Studies in Patients Treated With Chemotherapy: A Scoping Review.

Moon C, Wilson R, Gonzalo-Encabo P, Kang D, Mithani S, Dieli-Conwright C Integr Cancer Ther. 2024; 23:15347354241265349.

PMID: 39045709 PMC: 11271141. DOI: 10.1177/15347354241265349.


Acceptability and feasibility of cognitive assessments with adults with primary brain cancer and brain metastasis: A systematic review.

Carlson M, Fradgley E, Yates D, Morris S, Tait J, Paul C Neurooncol Pract. 2023; 10(3):219-237.

PMID: 37188159 PMC: 10180383. DOI: 10.1093/nop/npac097.


Factors associated with perceived cognitive impairment in patients with advanced lung cancer: a cross-sectional analysis.

Takemura N, Ho M, Cheung D, Lin C Support Care Cancer. 2022; 30(11):9607-9614.

PMID: 36178636 DOI: 10.1007/s00520-022-07377-9.